Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry
Grace E. McKay(University of Wisconsin–Madison), Bridget E. Shields(University of Wisconsin–Madison), Katharina S. Shaw(Brigham and Women's Hospital), Lisa M. Arkin(University of Wisconsin–Madison), Karolyn A. Wanat(Medical College of Wisconsin), Michael J. Murphy(American Veterinary Medical Association), Alexandra Charrow(Brigham and Women's Hospital), Avrom S. Caplan(New York University), Charlotte LaSenna(University of Wisconsin–Madison), Alexandra Coromilas(Harvard University), Lunan Liu(New York University), Nina Punyamurthy(Medical College of Wisconsin), William Damsky(Yale University), K. M. Santiago Soltero(Brigham and Women's Hospital), Misha Rosenbach(Hospital of the University of Pennsylvania)
Cited by 3
Related Papers
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
|PubMed|2014|505
Computationally guided personalized targeted ablation of persistent atrial fibrillation
|Nature Biomedical Engineering|2019|318
Compendium of Experimental Cetane Number Data
|Unknown|2004|263
Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus
|Journal of Investigative Dermatology|2009|238
Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center
|Circulation Heart Failure|2019|188